Search results | cardiovascular


Cardiovascular Partnering Terms and Agreements

The Cardiovascular Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the cardiovascular partnering deals and agreements entered into by the worlds leading healthcare companies


Cardiovascular partnering – recent market research analysis 2009-2014

Recent market research analysis by Current Agreements shows that partnering in the last decade has seen an increase in cardiovascular deals with an increase in modern diagnostic technology development.

Cardiovascular partnering – recent deal analysis 2007-2013

Partnering deal analysis in the last decade has seen an increase in cardiovascular partnering with an increase in modern diagnostic technologies

miRagen and Servier in cardiovascular tie up could be worth $1 billion

The collaboration focuses on developing microRNA-based therapeutics for cardiovascular and muscle disease

Aspen Pharma: Partnering activity 2009-2014

Aspen Pharma, a global branded and generics pharmaceutical manufacturer, has found a place in the top 50 big pharma companies listed by Current Partnering.

Aspen Pharmacare – Africa’s biggest generic drugmaker

Aspen Pharmacare specialises in the production of branded and generic pharmaceuticals and is currently the biggest pharmaceutical company in South Africa taking a 15% share of the total market.

Bayer hungry for pharma deals to expand business

Big pharma company Bayer , is going hunting for pharma deals again, with its chief executive expected to tell media outlets  that it is looking for further takeover pharma deals. 

Regenerative Medicine deal trends article

The field of regenerative medicine is an up and coming new approach of targeting and treating diseases, it involves the repair and restoration of previously damaged tissues or organs in the body. The regenerative medicine market was worth $16bn in 2013 and industry analysts predict that this will leap to over $60bn by 2020. The more »

Current Agreements Deal Analysis Update : October 2014

This month we provide you with an overview of deal analysis in the life science sectors, covering partnering, M&A and financing in September 2014.

Top 50 pharma and biotech companies review – 2009 to 2014

The partnering and M&A  trends and deal analysis of the top 50 pharma and biotech companies reveals a flurry of data that is interesting to observe for efficient deal making.

Bioinformatics: recent life science partnering trend analysis

The bioinformatics partnering deal trend analysis 2009 to 2014 are reviewed in this article.


Sorry, your search returned no results.


Bayer and X-Chem in cardiovascular drug discovery program pact

X-Chem has licensed a second drug discovery program to Bayer Pharma pursuant to the multi-target collaboration the companies established in July 2012

IPO financing for Cardiovascular Systems

Cardiovascular Systems announced an upcoming IPO worth up to $70 million in net proceeds.

Amgen and Servier terminate cardiovascular pharma deals

Amgen and Servier have terminated pharma deals involving the cardiovascular drug Procoralan.

Amgen pharma deals Servier for cardiovascular drugs licensing

Amgen and Servier announced new pharma deals leveraging each company’s commitment to cardiovascular disease.

AstraZeneca in $100 million pharma deals with Karolinska Institutet for cardiovascular and metabolic disease joint venture

AstraZeneca and Karolinska Institutet enter pharma deals to establish a unique integrated cardiovascular and metabolic research centre as part of a $100 million joint venture.

Boehringer Ingelheim big pharma deals Athera Biotech for novel cardiovascular antibody option agreement

Athera Biotechnologies has entered into pharma deals involving an option agreement with Boehringer Ingelheim on a novel preclinical antibody program.

AstraZeneca & Fudan Univ collaborate in pharma partnering deal on cardiovascular disease

AstraZeneca, a big pharma company has ventured in a pharma partnering pact with Fundan Univ.

Abbott & St. Jude Medical lengthen pharma alliances deal for cardiovascular products

Abbott and St. Jude Medical announced Choice Alliance, a multi-year joint pharma alliances initiative that provides mutual U.S. customers access to a robust portfolio of interventional cardiology, cardiac rhythm management, electrophysiology and intravascular imaging and diagnostic technologies

Simcere and Bristol-Myers Squibb enter innovative partnership to develop cardiovascular compound

Bristol-Myers Squibb and Simcere have announced that the companies have expanded the strategic partnership formed last year to include a second collaboration in a different therapeutic area. 

AstraZeneca and University of Virginia sign strategic research collaboration to develop novel treatments for cardiovascular disease

The collaborative preclinical research projects will focus on identifying disease mechanisms and biological targets that have the potential to be starting points for successful and commercially viable treatments of these diseases, both major causes of cardiovascular morbidity and mortality worldwide. The financial terms of the deal were not disclosed.